Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
List of Authors:
3-Year Interim Results of the Percutaneous MONARC™ System for the Treatment of Functional Mitral Regurgitation
Functional mitral regurgitation (FMR) is frequently observed in heart failure pts with ischemic or dilated cardiomyopathy and associated with poor prognosis. The aim of the prospective, multicenter, non randomized feasibility study was to assess the safety and efficacy of a percutaneous coronary sinus approach, with the MONARC system to reduce FMR up to 3-years. Primary objective of the study is to evaluate the acute safety (30d, 90d) of the MONARC system in treating functional mitral regurgitation in heart failure patients. Secondary objective of the study is reduction in MR by at least one grade at 90 days.
The device is delivered within the coronary sinus via a jugular venous approach The device is composed of 3 components: Self expanding distal anchor, Self expanding proximal anchor and Bridge connecting the anchors.
A biodegradable suture is wound on the bridge and acts as a temporary spacer to hold the spring open in an elongated state. Over about 6 weeks, the suture material dissolves, and the bridge compresses, shortening the coronary sinus
Implantation of the MONARC system is feasible, easy and reproducible. The 3-years data shows 64% of patients are event free compared to baseline. And encouraging 36-months results compared to baseline in respect to MR reduction and clinical functional NYHA class reduction.
EVOLUTION I is solely a safety study. It has a small 3-year sample size and no control group which gave limited insight to clinical benefit.
EVOLUTION II is underway taking into account the lessons learned from EVOLUTION I including a prospective control group, MR and hemodynamic responses and clinical outcomes measuring NYHA class, 6MWT and QoL.